Exact Mass: 505.1809
Exact Mass Matches: 505.1809
Found 500 metabolites which its exact mass value is equals to given mass value 505.1809
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
alangiside
An organic heterotetracyclic compound that is an alkaloidal glycoside isolated from Alangium salviifolium.
N-(2-Fluoro-4-(methylsulfonyl)phenyl)-6-(4-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-5-nitropyrimidin-4-amine
beta-D-fructofuranosyl-(2->1)-alpha-D-[2-O-L-tyrosyl]glucopyranoside
Asp Thr Arg Asp
Glu Ser Arg Asp
Arg Asp Thr Asp
Glu Asp Gln Asp
Rocaglamide
Rocaglamide is an organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity. It has a role as a metabolite, an antineoplastic agent and an antileishmanial agent. It is an organic heterotricyclic compound, a monomethoxybenzene and a monocarboxylic acid amide. Rocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides. Rocaglamides are secondary metabolites of the plant genus Aglaia, and extracts of the plant have traditionally been used as a form of insect repellant due to its natural insecticidal properties. Reports of Aglaia anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species A. elliptifolia. Rocaglamide and a number of its derivatives (e.g. [didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of certain chemotherapy-resistant cancers. Rocaglamide is a natural product found in Aglaia rimosa, Aglaia elliptifolia, and other organisms with data available. An organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity.
2-[5-chloro-7-(3,5-dihydroxyhexanoyloxy)-3-[(1E,3E,5E)-hepta-1,3,5-trienyl]-7-methyl-6,8-dioxoisoquinolin-2-yl]acetic acid
Ala Asp Asp Trp
Ala Asp Trp Asp
Ala Glu Thr Trp
Ala Glu Trp Thr
Ala Thr Glu Trp
Ala Thr Trp Glu
Ala Trp Asp Asp
Ala Trp Glu Thr
Ala Trp Thr Glu
Cys Met Pro Arg
Cys Met Arg Pro
Cys Asn Asn Arg
Cys Asn Arg Asn
Cys Pro Met Arg
Cys Pro Arg Met
Cys Pro Thr Trp
Cys Pro Trp Thr
Cys Gln Gln Gln
Cys Arg Met Pro
Cys Arg Asn Asn
Cys Arg Pro Met
Cys Thr Pro Trp
Cys Thr Trp Pro
Cys Trp Pro Thr
Cys Trp Thr Pro
Asp Ala Asp Trp
Asp Ala Trp Asp
Asp Asp Ala Trp
Asp Asp Glu Lys
Asp Asp Glu Gln
Asp Asp Lys Glu
Asp Asp Gln Glu
Asp Asp Arg Thr
Asp Asp Thr Arg
Asp Asp Trp Ala
Asp Glu Asp Lys
Asp Glu Asp Gln
Asp Glu Glu Asn
Asp Glu Gly Trp
Asp Glu Lys Asp
Asp Glu Asn Glu
Asp Glu Gln Asp
Asp Glu Arg Ser
Asp Glu Ser Arg
Asp Glu Trp Gly
Asp Phe Pro Gln
Asp Phe Gln Pro
Asp Gly Glu Trp
Asp Gly Trp Glu
Asp Ile Met Gln
Asp Ile Gln Met
Asp Lys Asp Glu
Asp Lys Glu Asp
Asp Leu Met Gln
Asp Leu Gln Met
Asp Met Ile Gln
Asp Met Leu Gln
Asp Met Gln Ile
Asp Met Gln Leu
Asp Asn Glu Glu
Asp Pro Phe Gln
Asp Pro Gln Phe
Asp Gln Asp Glu
Asp Gln Glu Asp
Asp Gln Phe Pro
Asp Gln Ile Met
Asp Gln Leu Met
Asp Gln Met Ile
Asp Gln Met Leu
Asp Gln Pro Phe
Asp Arg Asp Thr
Asp Arg Glu Ser
Asp Arg Ser Glu
Asp Arg Thr Asp
Asp Ser Glu Arg
Asp Ser Arg Glu
Asp Ser Val Trp
Asp Ser Trp Val
Asp Thr Asp Arg
Asp Val Ser Trp
Asp Val Trp Ser
Asp Trp Ala Asp
Asp Trp Asp Ala
Asp Trp Glu Gly
Asp Trp Gly Glu
Asp Trp Ser Val
Asp Trp Val Ser
Glu Ala Thr Trp
Glu Ala Trp Thr
Glu Asp Asp Lys
Glu Asp Asp Gln
Glu Asp Glu Asn
Glu Asp Gly Trp
Glu Asp Lys Asp
Glu Asp Asn Glu
Glu Asp Arg Ser
Glu Asp Ser Arg
Glu Asp Trp Gly
Glu Glu Asp Asn
Glu Glu Asn Asp
Glu Glu Gln Thr
Glu Glu Thr Gln
Glu Phe Asn Pro
Glu Phe Pro Asn
Glu Gly Asp Trp
Glu Gly Trp Asp
Glu Ile Met Asn
Glu Ile Asn Met
Glu Lys Asp Asp
Glu Leu Met Asn
Glu Leu Asn Met
Glu Met Ile Asn
Glu Met Leu Asn
Glu Met Asn Ile
Glu Met Asn Leu
Glu Met Gln Val
Glu Met Val Gln
Glu Asn Asp Glu
Glu Asn Glu Asp
Glu Asn Phe Pro
Glu Asn Ile Met
Glu Asn Leu Met
Glu Asn Met Ile
Glu Asn Met Leu
Glu Asn Pro Phe
Glu Pro Phe Asn
Glu Pro Asn Phe
Glu Gln Asp Asp
Glu Gln Glu Thr
Glu Gln Met Val
Glu Gln Thr Glu
Glu Gln Val Met
Glu Arg Asp Ser
Glu Arg Ser Asp
Glu Ser Asp Arg
Glu Thr Ala Trp
Glu Thr Glu Gln
Glu Thr Gln Glu
Glu Thr Trp Ala
Glu Val Met Gln
Glu Val Gln Met
Glu Trp Ala Thr
Glu Trp Asp Gly
Glu Trp Gly Asp
Glu Trp Thr Ala
Phe Asp Pro Gln
Phe Asp Gln Pro
Phe Glu Asn Pro
Phe Glu Pro Asn
Phe Asn Glu Pro
Phe Asn Pro Glu
Phe Pro Asp Gln
Phe Pro Glu Asn
Phe Pro Asn Glu
Phe Pro Gln Asp
Phe Gln Asp Pro
Phe Gln Pro Asp
Gly Asp Glu Trp
Gly Asp Trp Glu
Gly Glu Asp Trp
Gly Glu Trp Asp
Gly Trp Asp Glu
Gly Trp Glu Asp
Ile Asp Met Gln
Ile Asp Gln Met
Ile Glu Met Asn
Ile Glu Asn Met
Ile Met Asp Gln
Ile Met Glu Asn
Ile Met Asn Glu
Ile Met Gln Asp
Ile Asn Glu Met
Ile Asn Met Glu
Ile Gln Asp Met
Ile Gln Met Asp
Lys Asp Asp Glu
Lys Asp Glu Asp
Lys Glu Asp Asp
Leu Asp Met Gln
Leu Asp Gln Met
Leu Glu Met Asn
Leu Glu Asn Met
Leu Met Asp Gln
Leu Met Glu Asn
Leu Met Asn Glu
Leu Met Gln Asp
Leu Asn Glu Met
Leu Asn Met Glu
Leu Gln Asp Met
Leu Gln Met Asp
Met Cys Pro Arg
Met Cys Arg Pro
Met Asp Ile Gln
Met Asp Leu Gln
Met Asp Gln Ile
Met Asp Gln Leu
Met Glu Ile Asn
Met Glu Leu Asn
Met Glu Asn Ile
Met Glu Asn Leu
Met Glu Gln Val
Met Glu Val Gln
Met Ile Asp Gln
Met Ile Glu Asn
Met Ile Asn Glu
Met Ile Gln Asp
Met Leu Asp Gln
Met Leu Glu Asn
Met Leu Asn Glu
Met Leu Gln Asp
Met Met Pro Gln
Met Met Gln Pro
Met Asn Glu Ile
Met Asn Glu Leu
Met Asn Ile Glu
Met Asn Leu Glu
Met Asn Asn Gln
Met Asn Gln Asn
Met Pro Cys Arg
Met Pro Met Gln
Met Pro Gln Met
Met Pro Arg Cys
Met Gln Asp Ile
Met Gln Asp Leu
Met Gln Glu Val
Met Gln Ile Asp
Met Gln Leu Asp
Met Gln Met Pro
Met Gln Asn Asn
Met Gln Pro Met
Met Arg Cys Pro
Met Arg Pro Cys
Asn Cys Asn Arg
Asn Cys Arg Asn
Asn Asp Glu Glu
Asn Glu Asp Glu
Asn Glu Glu Asp
Asn Glu Phe Pro
Asn Glu Pro Phe
Asn Phe Glu Pro
Asn Phe Pro Glu
Asn Met Asn Gln
Asn Met Gln Asn
Asn Asn Cys Arg
Asn Asn Met Gln
Asn Asn Gln Met
Asn Asn Arg Cys
Asn Pro Glu Phe
Asn Pro Phe Glu
Asn Gln Met Asn
Asn Gln Asn Met
Asn Arg Cys Asn
Asn Arg Asn Cys
Pro Cys Met Arg
Pro Cys Arg Met
Pro Cys Thr Trp
Pro Cys Trp Thr
Pro Asp Phe Gln
Pro Asp Gln Phe
Pro Glu Phe Asn
Pro Glu Asn Phe
Pro Phe Asp Gln
Pro Phe Glu Asn
Pro Phe Asn Glu
Pro Phe Gln Asp
Pro Met Cys Arg
Pro Met Met Gln
Pro Met Gln Met
Pro Met Arg Cys
Pro Asn Glu Phe
Pro Asn Phe Glu
Pro Gln Asp Phe
Pro Gln Phe Asp
Pro Gln Met Met
Pro Arg Cys Met
Pro Arg Met Cys
Pro Thr Cys Trp
Pro Thr Trp Cys
Pro Trp Cys Thr
Pro Trp Thr Cys
Gln Cys Gln Gln
Gln Asp Asp Glu
Gln Asp Glu Asp
Gln Asp Phe Pro
Gln Asp Pro Phe
Gln Glu Asp Asp
Gln Glu Glu Thr
Gln Glu Thr Glu
Gln Phe Asp Pro
Gln Phe Pro Asp
Gln Met Met Pro
Gln Met Asn Asn
Gln Met Pro Met
Gln Asn Met Asn
Gln Asn Asn Met
Gln Pro Asp Phe
Gln Pro Phe Asp
Gln Pro Met Met
Gln Gln Cys Gln
Gln Gln Gln Cys
Gln Thr Glu Glu
Arg Cys Met Pro
Arg Cys Asn Asn
Arg Cys Pro Met
Arg Asp Asp Thr
Arg Asp Glu Ser
Arg Asp Ser Glu
Arg Glu Asp Ser
Arg Glu Ser Asp
Arg Met Cys Pro
Arg Met Pro Cys
Arg Asn Cys Asn
Arg Asn Asn Cys
Arg Pro Cys Met
Arg Pro Met Cys
Arg Ser Asp Glu
Arg Ser Glu Asp
Arg Thr Asp Asp
Ser Asp Glu Arg
Ser Asp Arg Glu
Ser Asp Val Trp
Ser Asp Trp Val
Ser Glu Asp Arg
Ser Glu Arg Asp
Ser Arg Asp Glu
Ser Arg Glu Asp
Ser Val Asp Trp
Ser Val Trp Asp
Ser Trp Asp Val
Ser Trp Val Asp
Thr Ala Glu Trp
Thr Ala Trp Glu
Thr Cys Pro Trp
Thr Cys Trp Pro
Thr Asp Asp Arg
Thr Asp Arg Asp
Thr Glu Ala Trp
Thr Glu Glu Gln
Thr Glu Gln Glu
Thr Glu Trp Ala
Thr Pro Cys Trp
Thr Pro Trp Cys
Thr Gln Glu Glu
Thr Arg Asp Asp
Thr Trp Ala Glu
Thr Trp Cys Pro
Thr Trp Glu Ala
Thr Trp Pro Cys
Val Asp Ser Trp
Val Asp Trp Ser
Val Ser Asp Trp
Val Ser Trp Asp
Val Trp Asp Ser
Val Trp Ser Asp
Trp Ala Asp Asp
Trp Ala Glu Thr
Trp Ala Thr Glu
Trp Cys Pro Thr
Trp Cys Thr Pro
Trp Asp Ala Asp
Trp Asp Asp Ala
Trp Asp Glu Gly
Trp Asp Gly Glu
Trp Asp Ser Val
Trp Asp Val Ser
Trp Glu Ala Thr
Trp Glu Asp Gly
Trp Glu Gly Asp
Trp Glu Thr Ala
Trp Gly Asp Glu
Trp Gly Glu Asp
Trp Pro Cys Thr
Trp Pro Thr Cys
Trp Ser Asp Val
Trp Ser Val Asp
Trp Thr Ala Glu
Trp Thr Cys Pro
Trp Thr Glu Ala
Trp Thr Pro Cys
Trp Val Asp Ser
Trp Val Ser Asp
4-[[5-(acetylamino)-1-methyl-1H-indol-3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]-Benzamide
TERT-BUTYL ((S)-1-((S)-2-CARBAMOYLPYRROLIDIN-1-YL)-1-OXO-3-(1-TOSYL-1H-IMIDAZOL-4-YL)PROPAN-2-YL)CARBAMATE
(11ar)-(+)-10,11,12,13-tetrahydrodiindeno[7,1-de:1,7-fg][1,3,2]dioxaphosphocin-5-bis(r)-1phenylethyl]amine
(1-[(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-METHYL]-CYCLOHEXYL)-ACETICACID
4-Methoxyphenyl 3-O-Benzyl-2-deoxy-2-phthalimido-beta-D-glucopyranoside
9H-Carbazole, 9-[1,1-biphenyl]-4-yl-3-(4-chlorophenyl)-6-phenyl-
7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid
(S)-2-[[3,5-Bis(trifluoromethyl)phenyl]thioureido]-N-benzyl-N,3,3-trimethylbutanamide
Nefazodone hydrochloride
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D049990 - Membrane Transport Modulators Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].
4-(FMOC-2-AMINOETHYL)-6-DIBENZOFURANPROPIONIC ACID
Dasatinib hydrate
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
4-Methylumbelliferyl2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-b-D-glucopyranoside
4-Methylumbelliferyl 2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-Galactopyranoside
Adavivint
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor D000893 - Anti-Inflammatory Agents
5-chloro-2-propyl-3-[4-[4-[2-(2H-tetrazol-5-ylmethyl)phenyl]phenyl]phenyl]imidazo[4,5-b]pyridine
N-[4-[[2-methoxy-5-[4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methoxy]phenyl]acetamide
(11S,12aR,13aR)-12-ethenyl-11-(beta-D-glucopyranosyloxy)-2-hydroxy-3-methoxy-5,6,12,12a,13,13a-hexahydro-11H-pyrano[4,3:4,5]pyrido[2,1-a]isoquinolin-8-one
(3S)-3-[[[(2S)-1-[(2S)-2-[[(4-amino-3-chlorophenyl)-oxomethyl]amino]-3,3-dimethyl-1-oxobutyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-cyanopropanoic acid ethyl ester
3-(3-fluorophenyl)-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-[(3aS,4S,9bS)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
3-[(3aS,4R,9bS)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
4-[(5-acetamido-1-methylindol-3-yl)methyl]-3-methoxy-N-(2-methylphenyl)sulonylbenzamide
3-(3-fluorophenyl)-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
3-(3-fluorophenyl)-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
3-[(3aR,4S,9bR)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
[(1S)-2-[(2,5-difluorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
3-(4-fluorophenyl)-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
3-[(3aR,4R,9bR)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
[(1R)-2-[(2,5-difluorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(E)-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-3-[3-methoxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enamide
2-[5-chloro-7-(3,5-dihydroxyhexanoyloxy)-3-[(1E,3E,5E)-hepta-1,3,5-trienyl]-7-methyl-6,8-dioxoisoquinolin-2-yl]acetic acid
SRT 1720 (monohydrochloride)
SRT 1720 monohydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3[1].